Forward Pharma A/S (FWP) Earning Somewhat Negative News Coverage, Report Shows

News stories about Forward Pharma A/S (NASDAQ:FWP) have been trending somewhat negative recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Forward Pharma A/S earned a coverage optimism score of -0.05 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.2165662652713 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

A number of equities analysts have commented on the stock. BidaskClub downgraded shares of Forward Pharma A/S from a “buy” rating to a “hold” rating in a research report on Friday, November 3rd. ValuEngine upgraded shares of Forward Pharma A/S from a “hold” rating to a “buy” rating in a research report on Friday. Jefferies Group reaffirmed a “hold” rating and set a $6.00 price target (up from $5.00) on shares of Forward Pharma A/S in a research note on Wednesday, September 27th. Finally, Zacks Investment Research cut shares of Forward Pharma A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, November 28th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $17.00.

Forward Pharma A/S (NASDAQ FWP) traded up $0.03 during trading hours on Monday, hitting $4.14. 15,000 shares of the stock were exchanged, compared to its average volume of 71,156. Forward Pharma A/S has a fifty-two week low of $4.02 and a fifty-two week high of $33.00.

WARNING: This piece was originally published by Week Herald and is owned by of Week Herald. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at

Forward Pharma A/S Company Profile

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.

Insider Buying and Selling by Quarter for Forward Pharma A/S (NASDAQ:FWP)

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with's FREE daily email newsletter.

Leave a Reply